Deal of the Day — limited-time pharmacy picks!
Bderlo 150mg Tablet

Bderlo 150mg Tablet

Prescription requiredRx Required

Salt Composition: Erlotinib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

10 tablets in a strip

About The Product

Lung Cancer

Erlotinib is an anticancer medication included in Bderlo 150 mg Tablet. It is used to treat non-small lung cancer (NSCLC) and pancreatic cancer. For individuals with advanced or metastatic pancreatic cancer, it is given in combination with gemcitabine, another anticancer medication. Children and teenagers under the age of eighteen should not take Bderlo 150 mg tablets.

Uses

Pancreatic cancer
Non-small cell lung cancer

Side Effects

  • Some of the common side effects of the Bderlo 150mg Tablet are: Headache, Fever Loss of appetite Pain in the eyes Blurred vision High blood pressure Dry skin lack of sleep.
  • Vomiting Indigestion Nausea Reduced Kidney function, diarrhea, or constipation

How To Use

  • Bderlo 150mg Tablet is not a drug used for selfmedication; it should always be taken as directed by a physician.As advised by the physician, it can be taken either with or without food.For best results in its effectiveness, the Bderlo 150mg Tablet must be swallowed rather than chewed, opened, or crushed.
  • It is an oral drug that is given once daily, before meals, at the same time every day.
  • The Bderlo 150mg Tablet should not be taken for at least three hours before or after food.
  • Take it as prescribed by the physician.

How It Works

The epidermal growth factor receptor (EGFR), a protein involved in the development and metastasis of cancer cells, is inhibited by Bderlo 150mg Tablet. EGFR plays a crucial role in cell division, growth, and survival of unregulated cells and contributes to the spread of disease.

Bderlo 150mg Tablet inhibits EGFR activity, hence reducing or stopping the proliferation of cancer cells. It inhibits the cancer cells' signaling mechanisms.

Safety Advice

Alcohol
Drinking too much alcohol could damage a person's immunity and liver function. Alcohol consumption can cause dizziness, confusion, tiredness, and cognitive impairment, so it is advised not to consume alcohol while taking the Bderlo 150 mg Tablet.
Pregnancy
It is not advised to take the Bderlo 150 mg Tablet when pregnant because it affects the fetus. This is not for use in pregnant women.
Breast Feeding
Because there is a possibility that the Bderlo 150mg Tablet could be transferred to the developing infant through the mother's breast milk, it is not advised to consume it while nursing. It is widely regarded as dangerous, and there is not enough evidence in the clinical data on its adverse impacts on infants.
Driving
Taking a Bderlo 150 mg tablet while operating machinery may cause confusion or affect one's capacity to drive. The capsule may cause neurological side effects, such as fever or feeling dizzy. Until you feel better, don't drive.
Kidney
People with kidney issues can use the Bderlo 150 mg Tablet after consulting with the doctor. It may harm the kidneys if taken as self-medication.
Liver
People with severe liver illness should not use the Bderlo 150 mg Tablet. Whereas people with mild liver disease can use this solution, but it must be regularly monitored. Use caution and alter the dosage of the Bderlo 150mg Tablet as advised by your doctor.

FAQs

As soon as you remember, take the missed dose unless it's time for your next dose.

You should never take a double dose to make up for a missed one.

Reference

Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., & Albanell, J.

(2022). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Journal of Clinical Oncology, 20(21), 4292-4302. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.

Y., & Baselga, J. (2023).

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–non-small-cell lung cancer. Journal of Clinical Oncology, 21(12), 2237-2246.

Lynch, T. J., Bell, D.

W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B.

W., & Haber, D. A.

(2024). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–non-small-cell lung cancer to gefitinib.

New England Journal of Medicine, 350(21), 2129-2139. Reck, M., van Zandwijk, N., Gridelli, C., Baliko, Z., Rischin, D., Allan, S., & Heigener, D.

(2024). Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.

Journal of Thoracic Oncology, 5(10), 1616-1622. Wang Y, Schmid-Bindert G, Zhou C.

(2025). Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians.

Ther Adv Med Oncol.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026